The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 12, 2017, Pages 2814-2823

  Cullen, Lori M ^a   Schmidt, Madelyn R ^a   Morrison, Trudy G ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

F protein antibodies; G protein antibodies; Respiratory syncytial virus; Vaccine; Virus like particles

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS F PROTEIN; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS LIKE PARTICLE VACCINE; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NEWCASTLE DISEASE VIRUS; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; SECONDARY IMMUNIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MICE, INBRED BALB C; PROTEIN CONFORMATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS;

EID: 85021105792     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1329069     Document Type: Article

References (37)

1. Karron RA. Respiratory syncytial virus and parainfluenza virus vaccines. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines. 5th ed:Saunders-Elsevier; 2008:1146
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59; https://doi.org/10.1056/NEJMoa043951
3. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-84; https://doi. org/10.1128/CMR.13.3.371-384.2000
4. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999; 179:25-30; https://doi.org/10.1086/314567
5. Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R. Respiratory tract viral infections in bone marrow transplant patients. Transplant 2003; 76:142-6; https://doi.org/10.1097/01. TP.0000072012.26176.58
6. Hall CB, Long CE, Schnabel KD. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001; 33:792-6; https://doi.org/10.1086/322657
7. Power UF. Respiratory syncytial virus (RSV) vaccines-Two steps back for one leap forward. J Clin Virol 2008; 41:38-44; https://doi.org/10.1016/j.jcv.2007.10.024
8. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2012;239:149-66; https://doi.org/10.1111/j.1600-065X.2010.00972.x
9. Morrison TG, Walsh EE. Subunit and Virus-like Particle Vaccine Approached for Respiratory Syncytial Virus. In: Anderson LJ, Graham BS, eds. Challenges and opportunities for respiratory syncytial virus vaccines. Heidelberg, Berlin: Springer; 2013
10. Jardetsky TS, Lamb RA. A class act. Nature 2004; 427:307-8; https:// doi.10.1038/427307a
11. Lamb RA, Parks GD. Paramyxoviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields Virology. Fifth Edition ed. Philadelphia: LippincottWilliams & Wilkins; 2007:1450-96
12. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 2011; 108:9619-24; https:// doi.org/10.1073/pnas.1106536108
13. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes. J Virol 2011; 85:7788-96; https://doi.org/10.1128/JVI.00555-11
14. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science 2013; 340:1113-7; https://doi.org/10.1126/ science.1234914
15. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE, Yang Y. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013;342:592-8; https://doi.org/10.1126/science.1243283
16. Hall CB, Simoes EAF, Anderson LJ. Clinical and Epidemiologic Features of Respiratory Syncytial Virus. In: Anderson LJ, Graham BS, eds. Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Heidelberg, New York, Dordrecht, Londaon:Springer; 2013: 39-58
17. Glezen W, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J of Dis of Child 1986; 140:543-6
18. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011; 85:366-77; https://doi. org/10.1128/JVI.01861-10
19. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare M, Smith G. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice with no evidence of immunopathology. J Virol 2010; 84:1110-23; https://doi.org/10.1128/JVI.01709-09
20. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787-96; https://doi.org/10.1038/nri2868
21. McGinnes-Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. Murine Immune Responses to Virus-Like Particle-Associated Pre- and Postfusion Forms of the Respiratory Syncytial Virus F Protein. J of Virol 2015; 89:6835-47; https://doi.org/10.1128/ JVI.00384-15
22. Cullen LM, Blanco JCG, Morrison TG. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med 2015; 13:1-13; https://doi.org/10.1186/s12967-015-0705-8
23. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 2011; 17:248-50; https://doi.org/10.1038/nsmb.1723
24. Boyoglu-Barnum S, Todd SO, Chirkova T, Barnum TR, Gaston KA, Haynes LM. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology 2015; 483:117-25
25. Boyoglu-Barnum S, Todd SO, Chirkova T, Barnum TR, Gaston KA, Haynes LM, Tripp RA, Moore ML, Anderson LJ. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology 2015; 483:117-25; https://doi.org/10.1016/j. virol.2015.02.035
26. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol 2004; 17:165-81; https://doi.org/10.1089/0882824041310513
27. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001; 2:732-8; https:// doi.org/10.1038/90675
28. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917-28; https://doi.org/10.1056/ NEJM200106213442507
29. Gilman MSA, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, Mas V, Melero JA, Wright PF, Graham BS, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 2016; 1:1879; https:// doi.org/10.1126/sciimmunol.aaj1879
30. Collins PL, Crowe JE. Respiratory syncytial virus and metapneumovirus. 5 ed. Philadelphia: LippincottWilliams and Wilkins; 2007
31. Chirkova T, Boyoglu-Barnum S, Gaston KA, Malik FM, Trau SP, Oomens AG, Anderson LJ. Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses. J of Virol 2013; 87:13466-79; https://doi.org/10.1128/ JVI.01741-13
32. Rey GU, Miao C, Caidi H, Trivedi SU, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM. Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice. PLoS ONE 2013; 8:e83075; https://doi.org/10.1371/journal.pone.0083075
33. McGinnes LW, Pantua H, Laliberte JP, Gravel KA, Jain S, Morrison TG. Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol 2010; 84:4513-23; https://doi.org/10.1128/JVI.01931-09
34. McGinnes LW, Reitter J, Pantua HD, Morrison TG. Newcastle disease virus: propagation, quantification, and storage: John Wiley and sons, Inc; 2006
35. McGinnes LW, Morrison TG. Newcastle Disease Virus-Like Particles:Preparation, Purification, Quantification, and Incorporation of Foreign Glycoproteins. Current Protocols in Microbiology: John Wiley & Sons, Inc; 2013
36. Gravel KA, McGinnes LW, Reitter J, Morrison TG. The transmembrane domain sequence affects the structure and function of the Newcastle disease virus fusion protein. J Virol 2011; 85:3486-97; https://doi.org/10.1128/JVI.02308-10
37. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989; 63:2941-50.